Your browser doesn't support javascript.
loading
[Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board].
Akhmedzhanov, N M; Vezikova, N N; Voevoda, M I; Galyavich, A S; Gurevich, V S; Duplyakov, D V; Ezhov, M V; Karpov, Yu A; Kashtalap, V V; Konovalov, G A; Smolenskaya, O G; Yakovlev, A N.
Afiliación
  • Akhmedzhanov NM; National Medical Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation.
  • Vezikova NN; Petrozavodsk State University.
  • Voevoda MI; National Research Institute for Therapy and Preventive Medicine.
  • Galyavich AS; Kazan State Medical University.
  • Gurevich VS; Saint-Petersburg State University; North-Western State Medical University named after I.I. Mechnikov.
  • Duplyakov DV; Samara Region Clinical and Diagnostic Cardiology Centre.
  • Ezhov MV; National Medical Research Center for Cardiology of the Ministry of Healthcare of the Russian Federation.
  • Karpov YA; National Medical Research Center for Cardiology of the Ministry of Healthcare of the Russian Federation.
  • Kashtalap VV; Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases.
  • Konovalov GA; Clinical and Diagnostic Centre "Medsi".
  • Smolenskaya OG; Ural State Medical University.
  • Yakovlev AN; Federal State Budgetary Institution "Almazov National Medical Research Centre" of the Ministry of Health of the Russian Federation.
Kardiologiia ; 59(5S): 58-64, 2019 Jun 20.
Article en Ru | MEDLINE | ID: mdl-31221076
On April 9, 2018, the national advisory board "Improvement of outcomes in patients with recent ACS: the place of PCSK9 inhibitors" was held in Moscow. Leading Russian experts in the field of atherosclerosis and lipid-lowering treatment attended the board. The purpose of the Board was to determine the place of PCSK9 inhibitors in the improvement of outcomes in patients with recent (less than 1 year) acute coronary syndrome (ACS). During the Board, three major aspects of lipid-lowering treatment were discussed: 1) issues in reaching the target levels of LDL cholesterol in real clinical practice among patients with recent ACS; 2) the results of ODYSSEY OUTCOMES study and their role in the improvement of outcomes in patients with recent ACS; 3) treatment with PCSK9 inhibitors in the management of patients with recent (less than 1 year) ACS in everyday clinical practice, the role of lipid centers.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Coronario Agudo Límite: Humans Idioma: Ru Revista: Kardiologiia Año: 2019 Tipo del documento: Article Pais de publicación: Rusia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Coronario Agudo Límite: Humans Idioma: Ru Revista: Kardiologiia Año: 2019 Tipo del documento: Article Pais de publicación: Rusia